Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LingGuiQiHua Granule is a Traditional Chinese Medicine (TCM) formulation developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is currently being investigated for the treatment of early-stage heart failure with preserved ejection fraction (HFpEF). The formulation is designed based on TCM principles, likely focusing on warming yang and transforming qi to address the underlying pathophysiology of cardiac dysfunction and fluid retention. It is being evaluated in a multicenter, randomized, double-blind, placebo-controlled exploratory clinical trial in China to determine its efficacy and safety in improving clinical outcomes for HFpEF patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LingGuiQiHua Granule.